News Feed

October 25, 2016 - Foundation edge HC in thriller The struggle continued for Harrison ... +++ October 25, 2016 - Byer-Suckoo reacts to union president’s demotion As far as Minister of Labour Dr Est ... +++ October 25, 2016 - Six weeks and counting Six straight weeks! That’s how lo ... +++ October 25, 2016 - 50th celebrations boycott Member of Parliament for St Joseph ... +++ October 25, 2016 - Two sudden resignations at Flow Telecommunications giant Flow has b ... +++ October 25, 2016 - Dead wrong! Minister of Education Ronald Jones ... +++

WORLD-Promising progress with Ebola vaccine

ANNAPOLIS –– The first human trial of an experimental Ebola vaccine has produced promising results, American scientists said, raising hopes that protection from the deadly disease might be on the horizon.

All 20 healthy adults who received the vaccine in a trial run by researchers from the National Institutes of Health in Maryland produced an immune response and developed anti-Ebola antibodies, the NIH said yesterday.

None suffered serious side effects, although two people developed a brief fever within a day of vaccination.

The vaccine is being developed by the NIH’s National Institute Of Allergy And Infectious Diseases and British pharmaceutical giant GlaxoSmithKline. The process has been fast-tracked in light of the current catastrophic Ebola outbreak in West Africa, which has claimed more than 5,000 lives.

“Based on these positive results from the first human trial of this candidate vaccine, we are continuing our accelerated plan for larger trials to determine if the vaccine is efficacious in preventing Ebola infection,” said Anthony Fauci, director of the National Institute Of Allergy And Infectious Diseases.

In this trial, genetic material from two strains of the Ebola virus, Sudan and Zaire, was delivered using a chimpanzee cold virus that does not harm humans. The vaccine does not contain the Ebola virus and cannot cause a person to be infected with Ebola, the NIH said. The current outbreak involves the Zaire strain.

The adults, volunteers ages 18 to 50, were split into two groups. Half received an intramuscular injection of vaccine at a lower dose and ten received the same vaccine at a higher dose,
the NIH said.

Researchers tested the volunteers’ blood at two weeks and four weeks after vaccination to determine if anti-Ebola antibodies had been produced.

All 20 volunteers developed such antibodies within four weeks of receiving the vaccine, with levels higher in those who were given the higher-dose vaccine.

The researchers also looked to see if the vaccine prompted production of immune system cells called T cells, after a previous study on primates using the same vaccine suggested they may also help to protect from the disease.

They found that many of the volunteers did produce T cells, including CD8 T cells, which may play a crucial role in protecting against infection by Ebola viruses.

Four weeks after vaccination, the CD8 T cells were found in two volunteers who received the lower-dose vaccine and in seven who had the higher dose, the NIH said.

The two volunteers who briefly developed a fever had received the higher-dose vaccine.

Source: (CNN)

One Response to WORLD-Promising progress with Ebola vaccine

  1. Fay Bedroppinemlikeadime Ann
    Fay Bedroppinemlikeadime Ann November 28, 2014 at 7:09 am

    Great now can we get a vaccine for “chikungunya”?!….-_- 30 year old with arthritis….annoying


Leave a Reply

Your email address will not be published. Required fields are marked *